PBC Powerlifting
Optimizing Your Management Skills with New Treatment Tools
Primary biliary cholangitis: epidemiology, prognosis, and treatment.
Trivella J, et al. Hepatol Commun. 2023;7(6):e0179.
Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment.
Lu M, et al. Clin Gastroenterol Hepatol. 2018;16(8):1342-1350.e1.
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery.
Abbas N, et al. JHEP Rep. 2023;6(1):100931.
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
Lammers WJ, et al. Gastroenterology. 2014;147(6):1338-1349.e5;quiz e15.
Efficacy and safety of elafibranor in primary biliary cholangitis.
Kowdley KV, et al. N Engl J Med. 2024;390(9):795-805.
A phase 3 trial of seladelpar in primary biliary cholangitis.
Hirschfield GM, et al. N Engl J Med. 2024;390(9):783-794.
Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis.
de Veer RC, et al. Am J Gastroenterol. 2023;118(7):1196-1203.
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis.
Nevens F, et al. N Engl J Med. 2016;375(7):631-643.
Fatigue in chronic liver disease patients: prevalence, pathophysiology, and management.
Kośnik A, et al. Prz Gastroenterol. 2022;17(1):21-27
Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise.
Corrigan M, et al. BMJ Open Gastroenterol. 2019;6(1):e000226
'It's as if PBC didn't exist': the illness experience of women affected by primary biliary cirrhosis.
Montali L, et al. Psychol Health. 2011;26(11):1429-1445
Primary biliary cholangitis, a rising health burden.
Elnagger MBA, et al. Explor Immunol. 2024;4:658–678.
Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review.
Smith HT, et al. Dig Dis Sci. 2023;68(6):2710–2730
Long-term efficacy and safety of elafibranor in primary biliary cholangitis: interim results from the open-label extension of the ELATIVE trial up to 3 years.
Kowdley KV, et al. [AASLD abstract 5041]. Presented at: The Liver Meeting; November 15-19, 2024; San Diego, CA
Impact of elafibranor on fatigue in patients with primary biliary cholangitis: interim results from the long-term open- label extension of the ELATIVE trial.
Swain MG, et al. [AASLD abstract 5042]. Presented at: The Liver Meeting; November 15-19, 2024; San Diego, CA
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE, et al. Liver Int. 2022;42(1):112-123
Check Out These Other PBC-Related CME Activities
Top 10 Things You Need to Know in the New PBC Landscape: A CME Top 10 Activity
Primary Biliary Cholangitis: A High-Yield Guide to PBC Management in the Era of PPAR Agonists
GUIDELINES
Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases.
Lindor KD, et al. Hepatology. 2019;69(1):394-419.
Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases.
Lindor KD, et al. Hepatology. 2022;75(4):1012-1013.
EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis.
European Association for the Study of the Liver. J Hepatol. 2017;67(1):145-172.
Guidelines on the diagnosis and management of primary biliary cholangitis (2021).
You H, et al. J Clin Transl Hepatol. 2023;11(3):736-746.
CLINICAL RESOURCES
American Association for the Study of Liver Disease (AASLD)
AASLD, founded in 1950, is a leading organization of scientists and health care professionals committed to preventing and curing liver disease.
European Association for the Study of the Liver (EASL)
EASL, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2024, EASL serves 7,000 members from 112 countries.
PATIENT RESOURCES AND ADVOCACY ORGANIZATIONS
PBCers Organization
The PBCers Organization is an online and in-person support group for people with PBC, care partners, and health care team members.
PBC Foundation
The PBC Foundation is a UK-based charity founded on the principles of providing PBC patients, their families, and friends with accurate, up-to-date information.
American Liver Foundation (ALF)
ALF was created in 1976 by the AASLD to promote education, advocacy, support services, and research for the prevention, treatment, and cure of liver disease.
Activity 1: Are You Missing PBC?
PBC Powerlifting: Optimizing Your Management Skills with New Treatment Tools
| Faculty: | Nancy S. Reau, MD |
| Release: | 03/20/2025 |
| Expiration: | 03/20/2026 |
